Researchers recently discovered that that inactivation of a protein called p62 in fat cells fuels aggressive, metastatic prostate cancer in mice. The findings suggest that mTOR inhibitors currently used to treat a wide range of cancers may have the unintended consequence of shutting down fat tissue metabolism and fueling tumor growth.